Comparison of 5-F-U and full fox with high-risk stage two and stage three patients

This chapter explores the comparison between 5-F-U alone and full fox in high-risk stage 2 and stage 3 patients. The speaker discusses the equivalence of Cape Siderine and 5-F-U, the non-inferiority of Cape Siderine in the EXAC trial, and the superior disease-free survival with Cape Socks compared to 5-F-U in another trial. The chapter also delves into the Mosaic trial, which revealed an improvement in disease-free survival with the addition of Oxile Plan, but highlights the risks and side effects associated with Oxile Plan, such as neuropathy. It further notes that Oxile Plan can be omitted in elderly patients without losing the benefits of chemotherapy.